Drug Profile
Research programme: mRNA therapeutics - MaxCyte/National Institute of Allergy and Infectious Diseases
Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator MaxCyte
- Class Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic granulomatous disease; Sickle cell anaemia
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA
- 28 Jul 2021 No recent reports of development identified for research development in Chronic-granulomatous-disease in USA
- 11 Jun 2018 MaxCyte establishes CRADA with National Heart, Lung, and Blood Institute for the development of mRNA therapeutics in Sickle cell disease